Anemia management in chronic kidney disease

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Background:

• Anemia is a frequent and serious complication of chronic kidney disease (CKD), impacting patient quality of life.
• Recombinant human erythropoietin (rHuEPO) revolutionized CKD anemia management since 1989.
• Recent findings indicate potential harm from higher hemoglobin targets, leading to more cautious ESA prescribing.

Purpose of the Study:

• To review the current and future status of erythropoiesis-stimulating agent (ESA) treatment in CKD.
• To assess factors contributing to uncertainty and the need for further research in ESA therapy.
• To address concerns regarding overuse, financial motives, and adverse effects associated with rHuEPO.

Main Methods:

• This is a review article, synthesizing existing evidence and expert opinion.
• Analysis of factors influencing ESA prescribing patterns and patient outcomes.
• Examination of regulatory perspectives from agencies like CMS and FDA.

Main Results:

• ESA treatment has significantly improved CKD patient lives but faces scrutiny over safety and cost.
• Debate exists regarding the overuse of rHuEPO, driven by financial incentives and leading to adverse events.
• Current evidence necessitates a reevaluation of ESA use and hemoglobin targets.

Conclusions:

• Optimal anemia management in CKD requires a robust evidence base.
• Rigorous research is essential to resolve the ongoing debate on appropriate ESA utilization.
• The scientific community must support further studies to ensure evidence-based anemia care in renal patients.